8 October 2024 UK-based AviadoBio, a LifeArc Ventures portfolio company, and Astellas Pharma today announced an exclusive option and license agreement for AVB-101.
Cambridge, Massachusetts-based Prime Medicine, a company delivering on the promise of Prime Editing to provide lifelong cures to patients, has announced its launch with $315 million in financing. 14 July 2021
German contract development and manufacturing company ProBioGen yesterday announced that they have entered into a research license agreement with US biotech Heat Biologics for both ProBioGen's Transposase System DirectedLuck as well as for its proprietary suspension HEK293 cell line. 14 July 2021
US biotech major Biogen has entered into a license and collaboration agreement for orelabrutinib, an oral small molecule Bruton’s tyrosine kinase inhibitor (BTKi) for the potential treatment of multiple sclerosis (MS), with China’s InnoCare Pharma. 13 July 2021
The Russian government is considering allowing foreign vaccines against COVID-19 to enter the domestic market, according to recent statements by some senior state officials and some local media reports, reports The Pharma Letter’s local correspondent. 13 July 2021
Ionis Pharmaceuticals has exercised its option and entered into an exclusive worldwide license and collaboration agreement with Bicycle Therapeutics for tissue-targeted delivery of oligonucleotide therapeutics. 13 July 2021
The US Food and Drug Administration has approved Darzalex Faspro (daratumumab and hyaluronidase-fihj) in combination with pomalidomide and dexamethasone for adult patients with multiple myeloma who have received at least one prior line of therapy including lenalidomide and a proteasome inhibitor. 13 July 2021
Hutchmed says that the first commercial sale in China of Orpathys (savolitinib), the Chinese firm's oral, potent, and highly selective small molecule inhibitor of MET, a receptor tyrosine kinase, occurred on July 12, 2021. 13 July 2021
Shares in New Jersey, USA-based Celldex Therapeutics leapt by a quarter on Monday, after the firm announced positive results from an ongoing Phase Ib trial of CDX-0159. 13 July 2021
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for ASP3772 for the prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes included in ASP3772 in adults aged 50 years and older. 13 July 2021
The University of Texas MD Anderson Cancer Center and Hummingbird Bioscience have announced the launch of a multi-year strategic research collaboration to investigate and evaluate HMBD-002, the Texas biotech’s VISTA antagonist antibody. 12 July 2021
England’s health technology assessor, the National Institute for Health and Care Excellence (NICE), has dealt a blow to Orchard Therapeutics’ reimbursement goals for atidarsagene autotemcel. 12 July 2021
Data from two Phase II studies investigating bemcentinib in hospitalized COVID-19 patients have been presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) by Norwegian biotech BerGenBio. 12 July 2021
Prothena Corp shares were up nearly 6% at $62.70 in pre-market New York trading, as the Ireland-headquartered biotech announced a definitive purchase agreement with Danish diabetes care giant Novo Nordisk. 12 July 2021
French vaccines developer Valneva has been awarded Breakthrough Therapy designation for its single-shot chikungunya vaccine candidate, VLA1553, by the US Food and Drug Administration (FDA). 12 July 2021
Belgian cell therapy company Bone Therapeutics, which is addressing unmet medical needs in orthopedics and other diseases, has appointed Anne Leselbaum as chief medical officer (CMO), effective August 23, 2021. 12 July 2021
The controversy over the approval of Alzheimer’s med Aduhelm (aducanumab) has deepened, as the acting head of the US Food and Drug Administration called for an investigation into her agency’s own actions. 12 July 2021
The US Food and Drug Administration has granted Padcev (enfortumab vedotin-ejfv) regular approval, in addition to approving a new indication for adult patients with locally-advanced or metastatic urothelial cancer who are ineligible for cisplatin-containing chemotherapy and have previously received one or more prior lines of therapy. 10 July 2021
Japanese drug major Chugai Pharmaceuticals has entered into an option and license agreement with Chinese biotech Alebund Pharmaceuticals (Hong Kong), regarding Chugai’s EOS789, an investigational agent under development for hyperphosphatemia. 10 July 2021
The USA's Institute for Clinical and Economic Review (ICER) has released an Evidence Report assessing the comparative clinical effectiveness and value of a host of therapies for atopic dermatitis (AD). 9 July 2021
The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) held its July meeting this past week, and today reported on safety issues with a leukemia drug and four COVID-19 vaccines. 9 July 2021
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
Cambridge, USA-based City Therapeutics has announced its launch with a vision to lead the future of RNA interference (RNAi)-based medicine. 9 October 2024
Zephyrm Bioscience, a Cayman Islands-based biotech, has filed for an initial public offering (IPO) in Hong Kong, seeking to raise additional capital to advance its cell therapy pipeline. 9 October 2024
Privately-held UK biotech Curve Therapeutics has announced the appointment of Rab Prinjha as chief research and development (R&D) officer. 9 October 2024
UK-based AviadoBio, a LifeArc Ventures portfolio company, and Astellas Pharma today announced an exclusive option and license agreement for AVB-101. 8 October 2024
China-headquartered clinical-stage biotech MediLink Therapeutics has announced a global clinical trial collaboration and supply agreement with US major Amgen. 8 October 2024
UK-based Mestag Therapeutics has entered into a license and collaboration agreement with Merck & Co to explore new therapeutic options for inflammatory diseases. 8 October 2024
With its recent US Food and Drug Administration (FDA) approval, Eli Lilly’s Ebglyss (lebrikizumab) adds a new competitor to the atopic dermatitis (AD) market. 8 October 2024
US clinical-stage biotech OnKure Therapeutics has announced the completion of its previously announced merger with Reneo Pharmaceuticals. 8 October 2024
Daejeon-based Orum Therapeutics, a specialist in degrader-antibody conjugates (DAC), has filed for an initial public offering (IPO) on South Korea's Kosdaq market. 7 October 2024
Orchard Therapeutics has signed an exclusive distribution agreement with Turkish drugmaker Er-Kim, for the gene therapy Libmeldy (atidarsagene autotemcel). 7 October 2024
Cambridge, USA-based biotech Judo Bio has announced the company’s launch and $100 million in initial financing, including seed financing and Series A. 7 October 2024
Mosaic Therapeutics, a UK-based oncology therapeutics company dedicated to resolving cancer’s complexity to power new combination therapies for patients, has announced the appointment of Barry Davies as chief scientific officer. 7 October 2024
ABL Bio Corp on Friday revealed that it has entered into a clinical trial collaboration and supply agreement with MSD (the ex-US/Canada trading name of Merck & Co. 7 October 2024
BeiGene has launched Tevimbra (tislelizumab) in the USA for the treatment of certain adults with esophageal squamous cell carcinoma (ESCC), after chemo. 7 October 2024
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
A clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role.